Pfizer 2011 Annual Report Download - page 22

Download and view the complete annual report

Please find page 22 of the 2011 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 117

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117

Financial Review
Pfizer Inc. and Subsidiary Companies
Nutrition Operating Segment
•Nutrition unit revenues increased 15% in 2011, compared to 2010, reflecting higher operational revenues of 11% and the favorable
impact of foreign exchange of 4%. The operational revenue increase was primarily due to increased demand for premium products,
launches of new products and strength in China and the Middle East.
2010 vs. 2009
Animal Health and Consumer Healthcare Operating Segment
•Revenues from Animal Health increased 29% in 2010, compared to 2009, reflecting the inclusion of operational revenues from legacy
Wyeth Animal Health products of 22%, higher operational revenues from legacy Pfizer Animal Health products of 4% due primarily to
growth in the companion animal and livestock businesses, as well as the favorable impact of foreign exchange of 3%.
Revenues—Major Biopharmaceutical Products
Revenue information for several of our major biopharmaceutical products follows:
(MILLIONS OF DOLLARS) YEAR ENDED DECEMBER 31, % CHANGE
PRODUCT PRIMARY INDICATIONS 2011 2010 2009 11/10 10/09
Lipitor Reduction of LDL cholesterol $9,577 $10,733 $11,434 (11) (6)
Lyrica Epilepsy, post-herpetic neuralgia and diabetic
peripheral neuropathy, fibromyalgia
3,693 3,063 2,840 21 8
Prevnar 13/Prevenar 13(a) Vaccine for prevention of pneumococcal
disease
3,657 2,416 — 51 *
Enbrel (Outside the U.S. and
Canada)(a)
Rheumatoid, juvenile rheumatoid and psoriatic
arthritis, plaque psoriasis and ankylosing
spondylitis
3,666 3,274 378 12 *
Celebrex Arthritis pain and inflammation, acute pain 2,523 2,374 2,383 6—
Viagra Erectile dysfunction 1,981 1,928 1,892 32
Norvasc Hypertension 1,445 1,506 1,973 (4) (24)
Zyvox Bacterial infections 1,283 1,176 1,141 93
Xalatan/Xalacom Glaucoma and ocular hypertension 1,250 1,749 1,737 (29) 1
Sutent Advanced and/or metastatic renal cell
carcinoma (mRCC) and refractory
gastrointestinal stromal tumors (GIST) and
advanced pancreatic neuroendocrine tumor
1,187 1,066 964 11 11
Geodon/Zeldox Schizophrenia; acute manic or mixed episodes
associated with bipolar disorder;
maintenance treatment of bipolar mania
1,022 1,027 1,002 —2
Premarin family(a) Menopause 1,013 1,040 213 (3) *
Genotropin Replacement of human growth hormone 889 885 887 ——
Detrol/Detrol LA Overactive bladder 883 1,013 1,154 (13) (12)
Vfend Fungal infections 747 825 798 (9) 3
Chantix/Champix An aid to smoking cessation treatment 720 755 700 (5) 8
BeneFIX(a) Hemophilia 693 643 98 8*
Effexor(a) Depression and certain anxiety disorders 678 1,718 520 (61) *
Zosyn/Tazocin(a) Antibiotic 636 952 184 (33) *
Pristiq(a) Depression 577 466 82 24 *
Zoloft Depression and certain anxiety disorders 573 532 516 83
Caduet Reduction of LDL cholesterol and hypertension 538 527 548 2(4)
Revatio Pulmonary arterial hypertension (PAH) 535 481 450 11 7
Medrol Inflammation 510 455 457 12 —
ReFacto AF/Xyntha(a) Hemophilia 506 404 47 25 *
Prevnar/Prevenar (7-valent)(a) Vaccine for prevention of pneumococcal
disease
488 1,253 287 (61) *
Zithromax/Zmax Bacterial infections 453 415 430 9(3)
Aricept(b) Alzheimer’s disease 450 454 435 (1) (4)
Fragmin Anticoagulant 382 341 359 12 (5)
Cardura Hypertension/Benign prostatic hyperplasia 380 413 457 (8) (10)
Rapamune(a) Immunosuppressant 372 388 57 (4) *
Aromasin Breast cancer 361 483 483 (25) —
BMP2(a) Development of bone and cartilage 340 400 81 (15) *
Relpax Treat the symptoms of migraine headache 341 323 326 6(1)
Xanax XR Anxiety disorders 306 307 318 —(3)
Tygacil(a) Antibiotic 298 324 54 (8) *
Neurontin Seizures 289 322 327 (10) (2)
Diflucan Fungal infections 265 278 281 (5) (1)
Arthrotec Osteoarthritis and rheumatoid arthritis 242 250 270 (3) (7)
Unasyn Injectable antibacterial 231 244 245 (5) —
Sulperazon Antibiotic 218 213 204 24
Skelaxin(c) Muscle relaxant 203 ——**
Inspra High blood pressure 195 157 130 24 21
Dalacin/Cleocin Antibiotic for bacterial infections 192 214 241 (10) (11)
Methotrexate Severe psoriasis 191 164 21 16 *
Toviaz Overactive bladder 187 137 59 36 132
Somavert Acromegaly 183 157 147 17 7
Alliance revenues(d) Various 3,630 4,084 2,925 (11) 40
All other(e) Various 6,768 6,194 4,913 926
2011 Financial Report 21